Basics ADMA Biologics Inc ADMA Biologics Inc is a biopharmaceutical company. The company develops and manufactures specialty plasma-based biologics for the proposed treatment of immune deficiencies and prevention of certain infectious diseases. IPO Date: October 18, 2013 Sector: Healthcare Industry: Biotech Market Cap: $3.7B Activated in VL: True Average Daily Range Avg Daily Range: $0.16 | 2.75% Avg Daily Range (30 D): $0.32 | 2.12% Avg Daily Range (90 D): $0.31 | 1.92% Institutional Daily Volume Avg Daily Volume: 1.61M Avg Daily Volume (30 D): 3.2M Avg Daily Volume (90 D): 2.84M Trade Size Avg Trade Size (Sh.): 182 Avg Trade Size (Sh.) (30 D): 92 Avg Trade Size (Sh.) (90 D): 88 Institutional Trades Total Inst.Trades: 1,949 Avg Inst. Trade: $3.4M Avg Inst. Trade (30 D): $3.36M Avg Inst. Trade (90 D): $3.42M Avg Inst. Trade Volume: .31M Avg Inst. Trades (Per Day): 2 Market Closing Trades Avg Closing Trade: $5.47M Avg Closing Trade (30 D): $6.82M Avg Closing Trade (90 D): $7.51M Avg Closing Volume: 504.49K     News Aug 7, 2025 @ 2:00 PM Plasma Derived Medicine Market to Reach USD 37.4 B... Source: Towards Healthcare Jul 30, 2025 @ 11:00 AM ADMA Biologics to Report Second Quarter 2025 Finan... Source: Adma Biologics, Inc. May 6, 2025 @ 8:11 PM 3 Mid-Cap Medical Stocks Outperforming the Market Source: Marketbeat.Com Apr 7, 2025 @ 11:00 AM ADMA Biologics Statement on Tariffs Source: N/A Mar 4, 2025 @ 6:50 PM BREAKING: Block & Leviton Investigating ADMA Biolo... Source: Block & Leviton Financials   TTM Q3 2025 Q2 2025 Basic EPS $.89 $.15 $.14 Diluted EPS $.86 $.15 $.14 Revenue $ 488.56M $ 134.22M $ 121.98M Gross Profit $ 267.28M $ 75.63M $ 67.23M Net Income / Loss $ 209.45M $ 36.43M $ 34.22M Operating Income / Loss $ 167.02M $ 51.01M $ 42.8M Cost of Revenue $ 221.28M $ 58.6M $ 54.76M Net Cash Flow $ -25.32M $ -28.9M $ 18.66M PE Ratio 17.85